Federal Register (80 FR 28624)) (the 2015 request for nominations notice).

Although that draft guidance was subsequently withdrawn in November 2017, FDA received over 30 comments containing nominations for multiple bulk drug substances in response to the 2015 request for nominations notice. FDA's approach for determining whether to include a bulk drug substance on the list described in the 2015 request for nominations notice was substantially the same as the approach described above for including a bulk drug substance on the "List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals" in accordance with GFI #256. Therefore, and in keeping with our intention as stated in the 2019 request for nomination notice, the Agency is including certain of these nominated bulk drug substances on this List. For other of these nominated bulk drug substances, finished drugs containing the bulk drug substances in the appropriate dosage form and strength have subsequently been approved; thus, these nominated bulk drug substances will not appear on the List.

Some bulk drug substances were nominated in response to the 2015 request for nominations notice with insufficient supporting information. FDA subsequently searched for additional supporting information for these bulk substances, conducted further review, and added those with sufficient supporting information to the "List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals."

In addition, on its own initiative, FDA has identified certain bulk drug substances that are used in minor species. Several have been evaluated and are included on the "List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals." Those identified bulk drug substances still under evaluation are included on "Bulk Drug Substances Currently Under Review." As FDA continues to identify and evaluate bulk drug substances that are used in minor species, we also encourage outside nominations.

Dated: April 11, 2022.

Lauren K. Roth,

Associate Commissioner for Policy. [FR Doc. 2022–08018 Filed 4–13–22; 8:45 am] BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Mechanisms of Memory and Sound Processing.

Date: April 26, 2022.

Time: 1:00 p.m. to 3:00 p.m. *Agenda:* To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Sepandarmaz Aschrafi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4040D, Bethesda, MD 20892, (301) 451.4251, Armaz.aschrafi@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 8, 2022.

Victoria E. Townsend,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–07958 Filed 4–13–22; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Dental & Craniofacial Research; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Dental and Craniofacial Research Council.

The meeting will be held as a virtual meeting and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (*http://videocast.nih.gov/*).

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Dental and Craniofacial Research Council. Date: May 18, 2022.

Open: 10:00 a.m. to 1:30 p.m.

Agenda: Report of the Director, NIDCR and concept clearances.

Place: National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Closed: 2:00 p.m. to 3:30 p.m.

Agenda: To review and evaluate grant

applications.

Place: National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Lynn M. King, Ph.D., Executive Secretary, Division of Extramural Activities, National Institute of Dental Craniofacial Research, 6701 Democracy Blvd., Room 960, Bethesda, MD 20892–4878, (301) 594–5006, Lynn.King@nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: http:// www.nidcr.nih.gov/about, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: April 8, 2022.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–07957 Filed 4–13–22; 8:45 am] BILLING CODE 4140–01–P